These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37078530)

  • 1. Preliminary report on the short-term efficacy and safety of SAPO-S1 therapy for locally advanced gastric cancer with a deep learning perspective.
    Lin Y; Zhang L; Zhang X; Wei X; Liu X; Xie Y; Han G
    Biotechnol Genet Eng Rev; 2024 Nov; 40(3):2704-2719. PubMed ID: 37078530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 3. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
    [No Abstract]   [Full Text] [Related]  

  • 4. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of the efficacy and influencing factors of preoperative P-SOX neoadjuvant chemotherapy regimen for progressive gastric cancer-construction of a clinical prediction model.
    Feng L; Shao L; Sun S; Zhang C; Cai B
    Cancer Med; 2023 Jun; 12(12):13031-13040. PubMed ID: 37096925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study.
    Chen J; Zhu J; Zhang Y; Wang W; Xia Y; Zhao J; Jiang T
    Medicine (Baltimore); 2023 Mar; 102(9):e33157. PubMed ID: 36862884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of continuous intra-arterial infusion neoadjuvant chemotherapy with surgery for locally advanced gastric cancer: a preliminary pilot study.
    Li B; Tang R; Zhang G; Cheng J; Chao M; Ding K
    J Gastrointest Oncol; 2022 Jun; 13(3):968-976. PubMed ID: 35837182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 9. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
    Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial.
    Guo H; Ding P; Sun C; Yang P; Tian Y; Liu Y; Lowe S; Bentley R; Li Y; Zhang Z; Wang D; Li Y; Zhao Q
    Front Oncol; 2022; 12():927781. PubMed ID: 36091139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety and short-term efficacy of apatinib combined with oxaliplatin and S-1 in the conversion treatment for gastric cancer with peritoneal metastasis].
    Ye ZS; Zeng Y; Wei SH; Wang Y; Chen S; Lin ZT; Wang ZW; Chen XL; Chen LC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):240-247. PubMed ID: 34645168
    [No Abstract]   [Full Text] [Related]  

  • 15. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
    BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
    Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
    World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Multicenter Phase II Study on the Feasibility and Efficacy of S-1 and Oxaliplatin Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Sakamoto Y; Morohashi H; Miura T; Tsutsumi S; Takahashi S; Hirama K; Wakiya T; Hakamada K
    Dis Colon Rectum; 2022 May; 65(5):663-671. PubMed ID: 33833145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.
    Jiang W; Zhou Y; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Guo H; Minervini F; Bongiolatti S; Yang N; Zhang Y; Tao M
    Transl Lung Cancer Res; 2022 Apr; 11(4):647-655. PubMed ID: 35529791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study.
    Zhang W; Li Y; Xue L; Qu D; Jiang Z; Wang Z; Yang Z; Zhou A
    Cancer Manag Res; 2021; 13():2163-2170. PubMed ID: 33688259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
    Xu H; Wang W; Yin J; Song C; Li L; Sun Z
    Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.